HIV-1 non-nucleoside reverse transcriptase inhibitors

Abstract

Two classes of anti-HIV drugs are currently marketed which target the HIV-1 reverse transcriptase (RT). The first explored class was the nucleoside RT inhibitors (NRTIs), such as AZT, ddI, ddC, 3TC, D₄T and abacavir, whereas the more recently launched class are the non-nucleoside RT inhibitors (NNRTI) currently comprising nevirapine (Viramune™, Boehringer Ingelheim), delavirdine (Rescriptor™, Pharmacia and Upjohn) and efavirenz (Sustiva™, Dupont Pharmaceuticals). The NNRTI class is in rapid development to find more clinically useful inhibitors, especially against inhibitor-induced mutant RT enzymes. This article covers development in the area of HIV-1 NNRTI from 1997 through early 2000.

• allosteric
• calanolide
• delavirdine
• DPC 961
• DPC 963
• efavirenz
• HIV-1 RT
• loviride
• nevirapine
• NNRTI
• non-nucleoside inhibitors
• NSC 667952
• PETT
• PNU-142721
• S-DABO
• trovirdine